EGFRvIII is a constitutively active, ligand-independent mutant of EGFR, best characterized in glioblastoma, where it promotes tumor aggressiveness, intratumoral heterogeneity, and resistance to conventional therapies. Here, EGFR is linked to glioblastoma.